Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (291-300 of 386) with videos related to

Pageof 39
Sort By:
Pharmacology & Therapeutics|February 9, 2006
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokinePankaj Gupta, Zao-zhong Su, Irina V Lebedeva, et al.
Autophagy|February 27, 2008
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cellsMargaret A Park, Adly Yacoub, Devanand Sarkar, et al.
Molecular Pharmacology|June 21, 2007
Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signalingClint Mitchell, Peyman Kabolizadeh, John Ryan, et al.
Molecular Cancer Therapeutics|February 20, 2007
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell linesClint Mitchell, Margaret A Park, Guo Zhang, et al.
Oncotarget|November 3, 2016
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myelomaJoel G Turner, Trinayan Kashyap, Jana L Dawson, et al.
Blood|May 31, 2008
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemiaSteven W Paugh, Barbara S Paugh, Mohamed Rahmani, et al.
Blood|August 13, 2015
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formationJustin Sperlazza, Mohamed Rahmani, Jason Beckta, et al.
Journal of Hematology & Oncology|August 26, 2016
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJoel G Turner, Jana L Dawson, Steven Grant, et al.
Molecular Pharmacology|April 20, 2006
OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cellsAdly Yacoub, Margaret A Park, David Hanna, et al.
Cancer Biology & Therapy|September 13, 2013
Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cellsHossein A Hamed, Swadesh K Das, Upneet K Sokhi, et al.
Pageof 39

Showing results (291-300 of 386) with videos related to

Sort By:
Pageof 39
Pharmacology & Therapeutics|February 9, 2006
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokinePankaj Gupta, Zao-zhong Su, Irina V Lebedeva, et al.
Autophagy|February 27, 2008
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cellsMargaret A Park, Adly Yacoub, Devanand Sarkar, et al.
Molecular Pharmacology|June 21, 2007
Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signalingClint Mitchell, Peyman Kabolizadeh, John Ryan, et al.
Molecular Cancer Therapeutics|February 20, 2007
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell linesClint Mitchell, Margaret A Park, Guo Zhang, et al.
Oncotarget|November 3, 2016
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myelomaJoel G Turner, Trinayan Kashyap, Jana L Dawson, et al.
Blood|May 31, 2008
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemiaSteven W Paugh, Barbara S Paugh, Mohamed Rahmani, et al.
Blood|August 13, 2015
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formationJustin Sperlazza, Mohamed Rahmani, Jason Beckta, et al.
Journal of Hematology & Oncology|August 26, 2016
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJoel G Turner, Jana L Dawson, Steven Grant, et al.
Molecular Pharmacology|April 20, 2006
OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cellsAdly Yacoub, Margaret A Park, David Hanna, et al.
Cancer Biology & Therapy|September 13, 2013
Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cellsHossein A Hamed, Swadesh K Das, Upneet K Sokhi, et al.
Pageof 39